drugset
drugset / Trial / NCT04665154

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

NCT04665154 ↗

Phase 1 Completed 80 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825 in healthy volunteers.

Timeline

Start
2019-06-07
Primary completion
2022-08-03
Completion
2022-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MAS825 Monoclonal antibody — Intravenous

Indications

No indication recorded.